Dr. Sarah Nikiforow, MD, PhD

Dr. Nikiforow practices at Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham.

Dr. Nikiforow's NPI, 1851508048, was assigned on May 17, 2007. Dr. Nikiforow graduated from Yale University School of Medicine in 2005. Dr. Nikiforow holds Massachusetts license 243632.

Dr. Nikiforow's primary practice is Brigham and Women's Hospital, at 75 Francis Street, Boston, MA 02115 in Suffolk County. The practice phone is (617) 732-5500.

Dr. Nikiforow's primary practice is Brigham and Women's Hospital in Boston, Massachusetts, part of Mass General Brigham. Dr. Nikiforow is also affiliated with Dana-Farber Cancer Institute. The medical group on file is Binney Medical Group. Dmand AI also links Dr. Nikiforow to 1 more hospital outpatient department, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nikiforow practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nikiforow's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Nikiforow is licensed in Massachusetts.

CMS data shows 46 Medicare services from Dr. Nikiforow across 1 procedure code in 2023, all of them office visits, for 16 Medicare patients. Medicare paid $2,509 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 16 Medicare patients who saw Dr. Nikiforow in 2024. The largest group is 85 and over, with 0 patients. 75% of them have high blood pressure, and 69% have chronic kidney disease. Their average risk score is 4.33, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nikiforow's median patient age at 63, with 43% women.

In 2024, Dr. Nikiforow wrote 167 Medicare Part D claims for 11 patients. 78% of them were for generic drugs. CMS names the drug for 33 of them, across 2 drugs with 11 or more claims each, at $306,369 in total drug cost. In 2023, CMS named 56 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Nikiforow for performance year 2024, reported as part of a group. Dr. Nikiforow accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 115 papers to Dr. Nikiforow, published from 2011 to 2025. 2020 was the busiest year, with 9. The most frequent topics are Hematopoietic Stem Cell Transplantation, Graft vs Host Disease and Immunotherapy, Adoptive. Dr. Nikiforow has published most often in Blood Adv. Dr. Nikiforow's most frequent co-authors are Robert J. Soiffer, MD, Joseph Harry Antin, MD and Vincent Trien-Vinh Ho, MD.

Dmand AI links Dr. Nikiforow to 1 clinical trial. Conditions studied include Lymphohistiocytosis, Hemophagocytic and Histiocytosis, Non-Langerhans-Cell.

CMS Open Payments shows 82 general payments to Dr. Nikiforow from 10 drug and device companies from 2018 to 2025. Consulting fees make up the largest share, 86% of the total. Sobi, Inc paid the most, $25,065. It also lists 2 research payments totaling $607 from 2022 to 2023.

Dr. Nikiforow graduated from Yale University School of Medicine in 2005.